Moderna stock rises on hantavirus vaccine work and flu data
Moderna's stock surged after the company confirmed early-stage research into a hantavirus vaccine, coinciding with a WHO-confirmed outbreak. Additionally, positive flu vaccine data published in a top medical journal boosted investor confidence. The biotech firm's shares rose sharply as markets reacted to these developments.
Key facts
- Moderna confirmed early-stage hantavirus vaccine research.
- WHO confirmed a hantavirus outbreak.
- Flu vaccine data published in a top medical journal.
- Moderna stock surged following the announcements.
Entities
Institutions
- Moderna
- World Health Organization
Sources
- Quartz —